Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is a publicly traded Financial Services sector company. As of October 21, 2026, DMAA trades at $10.87 with a market cap of $263.89M and a P/E ratio of 0.00. DMAA moved -0.09% today. Year to date, DMAA is +5.21%; over the trailing twelve months it is +5.79%. Its 52-week range spans $9.96 to $10.89. Rallies surfaces DMAA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Drugs Made In America amends Power Analytics merger to allow closing without APQC acquisition: Drugs Made In America Acquisition amended its merger with Power Analytics Global to allow closing without the APQC acquisition. The standalone valuation would be $1.71 billion, down from $2.85 billion, if the acquisition is not completed by November 1, 2026, or specified earlier triggers occur.
| Metric | Value |
|---|---|
| Price | $10.87 |
| Market Cap | $263.89M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.89 |
| 52-Week Low | $9.96 |
| Volume | 7.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $5.94M |
| Gross Margin | 0.00% |
DMAA analyst coverage data. Average price target: $0.00.